Printer Friendly
The Free Library
19,573,962 articles and books
Member login
User name  
Password 
 
Join us Forgot password?

CTI Files Registration Statement for Follow-on Public Offering.


Business Editors/Health & Medical Writers

SEATTLE--(BW HealthWire)--March 24, 2000

Cell Therapeutics, Inc. (cti) (Nasdaq:CTIC CTIC Conservation Technology Information Center
CTIC Chicago Title Insurance Company
CTIC Centro Tecnológico de la Información y de la Comunicación (Spanish: Center for the Development of Information and Communication Technologies in Asturias) 
) announced that it has filed a registration statement with the Securities and Exchange Commission for a follow-on offering Follow-On Offering

An offering of additional shares after a company has had an initial public offering.

Notes:
This sometimes means the company is strapped for cash. So they need to issue more shares to pay bills or finance a new project.
 of 3,000,000 shares of its common stock.

All shares will be offered by the Company. cti's common stock is traded on the Nasdaq National Market under the symbol "CTIC."

The shares will be offered by an underwriting group managed by CIBC World Markets CIBC World Markets is the investment banking division of the Canadian Imperial Bank of Commerce. It helps governments, large companies, and other large institutions obtain capital and credit and is a primary dealer in U.S. Treasury securities.  Corp. and U.S. Bancorp This article or section needs copy editing for grammar, style, cohesion, tone and/or spelling.
You can assist by [ editing it] now.
 Piper Jaffray Piper Jaffray & Co. (NYSE: PJC), often shortened to just Piper Jaffray or PiperJaffray, is a U.S. middle-market investment banking firm based in Minneapolis, Minnesota and is a focused on delivering financial advice, investment products and transaction execution . The underwriters will have an option to purchase an additional 450,000 shares to cover over-allotments, if any.

cti is committed to developing an integrated portfolio of products to make cancer a more treatable disease.

When publicly available, a copy of the prospectus related to the offering may be obtained from CIBC World Markets Corp. at 200 Liberty Street, New York New York, state, United States
New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of
, New York 10281, Attn: Prospectus Department or U.S. Bancorp Piper Jaffray at 222 South 9th Street, Minneapolis, MN 55402, Attn: Prospectus Department.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any State in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such State

http://www.businesswire.com/cnn/ctic.htm
COPYRIGHT 2000 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2000, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Mar 24, 2000
Words:276
Previous Article:NPI Begins Customer Shipments of Its All Gigabit and Stackable Layer 3 Switches ''Powered by NuWaveArchitecture''.
Next Article:Lucas Educational Systems Announces the Completion of a Private Placement Transaction.
Topics:



Related Articles
Cell Therapeutics, Inc. Announces Third Quarter Results.
Former Chiron Executive Appointed Chief Operating Officer at Cell Therapeutics Inc.
Cell Therapeutics, Inc. Reports 1998 Financial Results.
Cell Therapeutics, Inc. Advances Oncology Portfolio Backed by Strong Financial Resources.
Cell Therapeutics, Inc. Receives Fast Track Designation for Arsenic Trioxide; Company on Schedule for NDA Filing.
Cell Therapeutics, Inc. to Submit NDA by End of March.
Cell Therapeutics, Inc. Submits New Drug Application for Arsenic Trioxide.
Cell Therapeutics, Inc. Withdraws Follow-On Public Offering.
Wolters Kluwer acquires Compliance Tools Inc.
Milberg Weiss Announces the Filing of a Class Action Suit Against Cell Therapeutics Inc. On Behalf of Investors.

Terms of use | Copyright © 2012 Farlex, Inc. | Feedback | For webmasters | Submit articles